Meningitis (meningococcal diseases) is characterized by inflammation of the protective lining (meninges) present around the brain and spinal cord. It can be classified into infectious and non-infectious meningitis. Based on the types of organism, infectious meningitis is sub-divided into bacterial meningitis, viral meningitis, fungal meningitis, and parasitic meningitis. Bacterial meningitis occurs due to bacterial species such as hemophilus influenzae, listeria monocytogenes, neisseria meningitidis, and streptococcus pneumoniae. The infection can spread to the bloodstream, leading to septicemia. An infection by Neisseria meningitidis can result in meningococcal disease, which is associated with the simultaneous occurrence of meningitis and septicemia. Patients either recover or may suffer from long-term effects such as neurological defects. It is usually treated with antibiotics, and preventive measures involve the administration of vaccines.

PART 01: Executive summary

Highlights

PART 02: Scope of the report

Market overview

Top-vendor offerings

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

Key buying criteria

PART 05: Overview of vaccines

Understanding Meningococcal disease

Causes of meningococcal diseases

Signs and symptoms

Epidemiology

Vaccine approval process

PART 06: Market landscape

Market overview

Market size and forecast

Five forces analysis

PART 07: Market segmentation by composition

Mono vaccines

Combination vaccines

PART 08: Geographical segmentation

Global meningococcal vaccines market by geographical

segmentation 2015-2020

Meningococcal vaccines market in Americas

Meningococcal vaccines market in US

Meningococcal vaccines market in the Brazil

Meningococcal vaccines market in EMEA

Meningococcal vaccines market in Europe

Meningococcal vaccines market in APAC

Meningococcal vaccines market in Australia

PART 09: Market drivers

Increase in awareness about vaccination and

immunization programs

Designated as a traveler's vaccine

Inclusion in national immunization schedule

Threat of bioterrorism

Additional age group approval

PART 10: Impact of drivers

PART 11: Market challenges

Vaccine storage and handling issues

High cost associated with vaccine development

Stringent regulations

Emergence of local players

Adverse effects

PART 12: Impact of drivers and challenges

PART 13: Market trends

Availability of combination vaccines

Increase in strategic alliances and M&A

Focus on emerging markets

Public-private initiatives

PART 14: Vendor landscape

Competitive scenario

Market share analysis 2015

Sanofi

GlaxoSmithKline (GSK)

Pfizer

Other prominent vendors

PART 15: Appendix

List of abbreviations

PART 16: Explore Technavio